The new division’s first priority will be to develop over-the-counter wound treatment applications for Oxycyte. Oxycyte is the company’s perfluorocarbon therapeutic oxygen carrier.
Dr Diegelmann is a tenured professor of biochemistry and molecular biology, anatomy and emergency medicine at Virginia Commonwealth University Medical Center. He has worked with Oxycyte and understands its potential in wound care.
Chris Stern, chairman and CEO of Oxygen Biotherapeutics, said: “I view Bob Diegelmann as Virginia Commonwealth University’s wound care guru and I’m thrilled that he has contracted with us to be in charge of getting our topical and clinical wound indications to market.”